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Background: Chronic lumbar radicular pain can be described as neuropathic pain along the distribution of a
particular nerve root. The dorsal root ganglion has been implicated in its pathogenesis by giving rise to abnormal
impulse generation as a result of irritation, direct compression and sensitization. Chronic lumbar radicular pain is
commonly treated with medications, physiotherapy and epidural steroid injections. Epidural steroid injections are
associated with several common and rarer side effects such as spinal cord infarction and death. It is essential and
advantageous to look for alternate interventions which could be effective with fewer side effects.
Pulse radio frequency is a relatively new technique and is less destructive then conventional radiofrequency. Safety
and effectiveness of pulse radio frequency in neuropathic pain has been demonstrated in animal and humans
studies. Although its effects on dorsal root ganglion have been studied in animals there is only one randomized
control trial in literature demonstrating its effectiveness in cervical radicular pain and none in lumbar radicular pain.
Our primary objective is to study the feasibility of a larger trial in terms of recruitment and methodology. Secondary
objectives are to compare the treatment effects and side effects.
Methods/designs: This is a single-center, parallel, placebo-controlled, triple-blinded (patients, care-givers, and
outcome assessors), randomized control trial. Participants will have a history of chronic lumbar radicular pain for at
least 4 months in duration. Once randomized, all patients will have an intervention involving fluoroscopy guided
needle placement to appropriate dorsal root ganglion. After test stimulation in both groups; the study group will
have a pulse radio frequency treatment at 42°C for 120 s to the dorsal root ganglion, with the control group having
only low intensity test stimulation for the same duration. Primary outcome is to recruit at least four patients every
month with 80% of eligible patients being recruited. Secondary outcomes would be to assess success of
intervention through change in the visual analogue scale measured at 4 weeks post intervention and side effects.
Allocation to each group will be a 1:1 ratio with allocation block sizes of 2, 4, and 6.
Trial registration: ClinicalTrials.gov NCT01117870
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Chronic lumbar radicular pain (CLR) refers to symptoms
of neuropathic pain in the territory of the affected lumbar
nerve root. More precisely, the pathology in this condition
affects a particular nerve root after it exists from the spinal
canal, and before it becomes a part of the somatic nerve.
The quality of this pain is usually sharp, lancinating,
or burning. Clear distinction must be made between
radicular pain (as described above) and radiculopathy.
Radiculopathy refers to objective loss of sensory and/or
motor function as a result of conduction block and leads
to features of numbness, motor loss, wasting, weakness,
and loss of reflexes [1]. The patho-physiology of radicular
pain is complex, with mechanical [2] inflammatory [3,4],
and immunological factors playing a role. The dorsal root
ganglion (DRG) has been implicated in its pathogenesis by
giving rise to sustained impulse transmission as a result
of direct compression or as a site of hyper-excited struc-
ture. Prolonged compression presumably accompanied by
pathological changes in the nerve root or DRG causes
radicular pain to develop [5]. The majority of patients with
acute radicular pain due to a symptomatic herniated disc
improve with conservative or no treatment and have min-
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Figure 1 Randomized, placebo/sham controlled, double blinded trialgo on to suffer from significant chronic pain [6]. Radicular
pain is mostly treated with medications, physiotherapy,
and epidural steroid injections (ESI). ESI, although effect-
ive in reducing short-term pain in most patients, is asso-
ciated with side effects such as headaches, flushing, water
retention, metabolic and endocrine changes like glucose
intolerance, and adrenal suppression [7,8]. They are also
known to be associated with potentially serious side effects
such as spinal cord infarction and death secondary to
intra-arterial injection of particulate steroid preparations
[9]. It is clinically imperative and beneficial to look for
alternate interventions which could be effective with fewer
and/or lesser side effects.
Pulsed radio frequency (PRF) is a relatively new technique
derived from a well established and proven intervention
called thermal radiofrequency (RF) denervation (ablation)
[10]. Conventional RF treatment uses a constant output of
high-frequency electric current, producing controllable
tissue destruction surrounding the tip of the treatment can-
nula. Because of the thermal lesion (up to 80°C), it is asso-
ciated with non-selective damage to neural elements and is
known to cause deafferentation pain, which could be more
severe than the original pain [11]. The comparisons of PRF
and continuous RF are given in Table 1. Effectiveness ofCEBO
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demonstrated in animal studies and as well as studies done
on humans [12]. Various studies have demonstrated its pos-
sible mechanisms of action, including non-thermal effects
on DRG, selective inhibition of pain carrying fibers, and ac-
tivation of C-fos. At least two recent and well-conducted
studies [13,14] and one case series [15] are an indication of
its effectiveness specific to lumbar radicular pain. However,
there has been only one randomized controlled trial (RCT)
[16] in literature demonstrating its effectiveness in cervical
radicular pain and none in lumbar radicular pain. The
development and present use of PRF, as an interventional
tool in pain management, has been pictorially compared to
a ‘train running in reverse’ (as a refinement - came out to
be widely used and successful but never bench tested)
by Cohen and Zundert [17]. Unfortunately the use and
advocation of PRF as a novel and successful treatment for
many painful conditions is in practice without having the
necessary scientific evidence, especially in the form of well
controlled RCTs [18,19]. It has made many clinicians to
question its scientific basis and evidence in terms of specific
disease-based application [12,18-20]. Rapidly changing the-
ories regarding its mechanism of action have not helped
matters. In various evidence classifications schemes across
the world, well-controlled RCTs are seen as the gold stand-
ard evidence of the effects of treatments. To receive a class
I and grade A evidence classification, an intervention has to
have at least one positive, adequately powered and well-
conducted RCT or, preferably, a number of RCTs that con-
sistently show the benefit of therapy [21]. We conducted a
thorough literature search in MEDLINE (pubmed),
EMBASE, and Cochrane database - with the terms ‘pulsed
radiofrequency’, ‘pulse radiofrequency’, ‘pulse radiofrequency
of DRG’, ‘dorsal root ganglion treatment with pulsed radio-
frequency’, and ‘PRF-DRG’. No limits were applied for the
period of search. Up to 2010, we obtained 368 citations.
Abstracts pertaining to electrical field research and treat-
ment for non-painful conditions were omitted. Potentially
relevant articles were screened and articles pertaining only
to ‘PRF treatment in pain’ were selected giving rise toTable 1 Comparison of continuous vs. pulse RF
Continuous RF
First used Shealy 1975
Application Continuous RF energy for 90 s
Needle tip Parallel and by the side of target
Tissue temperature achieved Up to 80°C
Proposed mechanism of action Non-selective thermal destruction
Side effects Deafferentation syndrome
Duration of effect Potentially long lasting (months)
Use on peripheral nerves Cannot be used -contraindicated85 articles. Only abstract submissions or conference pro-
ceedings were not included. We observed that most of the
evidence regarding the use of PRF in chronic pain condi-
tions consists of retrospective and prospective case series.
Only a few RCTs concerning the use of PRF was found in
our literature search; Kroll et al. [22] and Tekin et al. [23]
on facet joint pain-PRF of medial branch, Erdine et al. [24]
on PRF of gasserian ganglion for trigeminal neuralgia, Van
Zundert et al. [16] and Simopoulos (pilot study) [25] for
radicular pain. The study by Van Zundert et al. is the
only RCT concerning the application of PRF-DRG for
cervical radicular pain. Its main limitation was inadequate
number of subjects. There has not been any RCT involving
PRF-DRG for lumbosacral radicular pain.
The resulting articles were then studied and grouped
into categories: A, basic science and animal experiments-
demonstrating its efficacy, safety and mechanisms of
action (summarized in Table 2); B, systematic reviews
(considered below); C, application of PRF for spinal pain
conditions-headache, back pain and radicular pain, and
application of PRF to DRG (summarized in Table 3); D,
application of PRF in various other painful clinical condi-
tions (not considered relevant for this study).
Systematic reviews
Because of the lack of sufficient RCTs systematic reviews
were considered. Although there have been at least eight
literature reviews on the use of radio frequency in chronic
pain, only six of them have included the use of PRF. Geurts
et al.’s [43] review considered the use of conventional RF
only, in spinal pain. Neimisto et al. [44] conducted a
systematic review in the frame work of Cochrane collabor-
ation; even this review was focused only on conventional
RF. Zundert et al. [45] could not make a detailed review of
PRF, as the available evidence was limited at that time.
Malik and Benzon [46] included studies concerning appli-
cation of both RF and PRF specifically to DRG in their
recent review. They included one RCT by Van Zundert on
cervical DRG and three retrospective studies and few case
series and reports. However their opinion on use of PRF ofPulsed RF
Sluijter and others 1998
RF energy in pulses of 20 ms with wash-out period of 480 ms
Perpendicular, pointing at the target
Up to 42°C
Neurobiological - by strong electrical fields
No side effects observed so far
? Relatively short duration
Has been effectively used in peripheral mono-neuropathies
Table 2 PRF in animal experiments demonstrating its effect and safety
Authors Study information Results Observations
Tun et al.
[26]
Histopathology and electron microscopy
of rat brain tissue after RF and PRF
Reversible histological changes with PRF, while
cellular necrosis seen with Cont RF
PRF is non-destructive and safe than RF
Cahana
et al. [27]
Acute effects of PRF and CRF on impulse
propagation and synaptic transmission in
rat hippocampus
Effects of PRF less destructive and reversible. At more
than 2000 μm, both RF and PRF did not affect the
cellular morphology, at 1000 μm only CRF and not
PRF destroyed the neuronal architecture
PRF is safer when compared to CRF; also
established the clinical effects with
differing distances from the RF probe
Higuchi
et al. [28]
Rat DRG exposed to PRF and CRF Only PRF led to increased C-Fos expression from the
superficial laminae of the dorsal horn within 3 h after
treatment
Action of PRF was demonstrated by C-Fos
expression, which is speculated to be a
mode of action of PRF
Erdine
et al. [29]
Rat DRG exposed to CRF and PRF Mitochondrial degeneration and loss of nuclear
membrane with CRF and only cellular edema with
PRF (reversible change)





Rat DRG CRF and PRF applied at 67° Demonstration of late trans-synaptic activity as C-Fos
seen even after 7 days in both RF and PRF
Late cellular activity observed by PRF;




CRF and PRF at 2° on rat DRG Only endoneurial edema and collagen deposition;
no irreversible changes seen
PRF depends on non destructive effects,
and temperature of 42° and below are not
associated with neural destruction
Hamman
et al. [32]
PRF applied to axotomised DRG and
sciatic nerve
Increased ATP -three positive cells with PRF of
axotomised DRG and not in sciatic nerve
Selective action of PRF on Aδ and C fibers,
sparing the more larger fibers
Hagiwara
et al. [33]
PRF on rats with adjuvant induced
hyperalgesia
PRF at 37° and 42°-successful in treating
hyperalgesia, when compared to CRF and sham
interventions The same effect was blocked by α-
adrenoceptor blocker Yohimbine
The analgesic effect of PRF may involve




Rat model - induction of neuropathic pain
by sciatic nerve ligation and PRF to DRG
PRF successful in decreasing the hyperalgesia
associated with neuropathic pain
Efficacy of PRF in neuropathic pain
Heavner
et al. [35]
Coagulation of egg white patterns with
CRF and PRF applied at various
temperatures
At 42°- no coagulation observed with PRF, and
pattern just observed at 60°, with CRF coagulation
observed even at 42°
Safety of PRF when applied at 42°
Vatansaver
et al. [36]
Neurothermal effects of PRF and CRF -
studied in sciatic nerve of rats, with
lesions applied at 400°C, 420°C, and 800°C
No neurological deficits at temperatures less than
800°C; however at 400°C, PRF was less damaging
than CRF
Relatively safety of PRF further established
at less than 42°C
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earlier article, Malik and Benzon [47] made a critical re-
view on the efficacy of PRF. They stated the need for
further RCTs in PRF in order to help the practicing pain
physician in their use of PRF for many chronic pain condi-
tions. Boxem et al. [48] reviewed RF and PRF with the
view of assimilating the present available evidence for their
use in various chronic pain conditions. The evidence was
supposedly similar for both RF and PRF in cervical radicu-
lar pain but they opined that PRF should be preferred as it
is associated with lesser side effects. Bryd and Mackey [49]
performed an excellent review of PRF including its history
and its applications in various pain conditions. Apart from
recognizing that evidence in the form of RCTs are lacking,
they stated that the emergence of PRF technology repre-
sents a promising step toward treating complicated pain
conditions. As the evidence in support of PRF accumu-
lates, it is likely that its potential to be applied more
broadly will also increase. Cahana et al. [12] did a litera-
ture review solely on PRF. Their literature search revealed
several prospective and retrospective studies along withmany case reports. Fifty-eight reports were considered in
the final evaluation. They observed that PRF treatment
elicits a genuine neurobiological phenomenon altering the
pain signal; however the mechanism of action is not com-
pletely elucidated. There are no major or significant side
effects related to PRF reported to date. The views and
positions of many senior and experienced clinicians on
PRF are conflicting. Some are convinced by the scientific
evidence that PRF is genuinely effective [10,17,50] for
neuropathic pain. However the consensus view points
towards inadequate evidence as compared to other
evidence-based treatments. Most are of the view that there
needs to be further studies (RCTs), which clearly estab-
lishes its role in specific target population [10,18-20,48,51].
In this ‘proof of concept’ study we would like to
answer the question, ‘whether PRF, when compared to
placebo, is effective in reducing pain in chronic lumbar
radiculopathy (CLR)’? With this rationale and purpose,
a feasibility study is being done to assess whether a
larger scale clinical study with the same methodology
can be done. This pilot study would also help in
Table 3 Studies demonstrating the effects of PRF on spinal pain conditions
Studies Patients and treatments Results Observations
Van Zundert et al.
[37]
18 patients with cervical headache and
cervico-brachialgia; PRF-DRG
13/18 patients >50% pain relief at 8 weeks, at
1 year 6 patients had continuing pain relief; no
complications reported
First documented evidence of PRF
treatment in cervical syndromes
Van Zundert et al.
[16] P, R, DB, RCT,
sham controlled
23 patients with Cervico brachial pain;
11 patients had PRF-DRG and 12 had
Sham
3 months - 82% patients in the PRF-DRG group
and 25–33% in the Sham group had successful
results (P= 0.02–0.03)
PRF-DRG may provide pain relief in
patients with cervico-brachial pain
Tsou et al. [38]
Retrospective
127 patients; group A - back pain
without lower limb pain, group B - back
pain with lower limb pain
Successful treatment shown; At 3 months: Group A
- 27/45 and Group B - 37/78 patients At 1 year:
Group A - 20–45 patients and Group B - 34/74
patients
Pulsed radiofrequency applied at the L-
2 DRG is safe and effective for treating
for chronic low-back pain
Kroll et al. [22]
Prospective, DB,
randomised
50 patients treated with CRF or PRF of
lumbar facets, and assessed with VAS,
ODI -measured at baseline and
3 months
No difference in the two groups, however over
time the CRF patients showed better scores than
PRF
Effects of PRF may be limited by time
when compared to CRF
Simopoulous
et al. [25] Pilot -
prospective RCT
26 patients with lumbosacral radicular
pain grouped to PRF-DRG or PRF-DRG
followed by CRF-DRG
At 2 months 70% of PRF showed significant
reduction of pain scores compared to 83% in CRF
after PRF, no statistical difference
PRF-DRG appears to be a good
treatment without side effects for
lumbosacral radicular pain
Lindner et al. [39]
Retrospective
study
48 patients with positive diagnostic
blockade of lumbar medial branch, had
PRF
21/29 patients with no previous surgery and 5/19
patients with previous surgery showed successful
pain relief at 4 months, significant difference in
PRF efficacy in between groups (P= 0.0028)
PRF of lumbar medial branch for
facetogenic pain is safe and works well
in patients who have not had back
surgeries
Texiera et al. [40]
Prospective, case
series
8 patients with discography confirmed
discogenic pain - intradiscal PRF
Significant drop in NRS scores at 3 months, 4
patients were reportedly pain free after 12 months
Intradiscal PRF merits a controlled
prospective study
Chao et al. [15] 154 patients with cervical (n= 49),
lumbar (n= 105) radicular pain due to
herniated disc and FBSS
At 3 months 27/49 in cervical and 52/105 in
lumbar patients had pain relief >50%
Application of PRF is a safe and useful
intervention for cervical and lumbar
radicular pain
Texiera et al. [14]
Retrospective
study
13 patients with lumbosacral radicular
pain due to herniated disc had PRF-DRG
Significant pain reduction (P= 0.01), was found in
11 patients from 4 weeks lasting up to 15 months,
only 1 patient had a small area of low sensation at
L3 area in the last follow-up
PRF may potentially be a viable
alternative for epidural steroid
injections in the treatment of radicular
pain
Shabat et al. [41]
Retrospective
28 patients with chronic neuropathic
pain of spinal origin had PRF-DRG
19 patients had successful pain relied lasting for an
year, with no reported complication
PRF is a safe and an effective procedure
for patients who suffer from chronic
neuropathic pain from spinal origin
Tekin et al. [23]
Prospective RCT
60 patients grouped with clinical
diagnosis of facet joint pain - grouped
into LA, PRF, and CRF groups
Pain relief in PRF and CRF better, however in the
follow-up period the relief was not sustained in
the PRF group
Pain relief with PRF is comparable to





114 patients with cervical and lumbar
pain, responsive to diagnostic medial
branch block-PRF
68 patients had significant pain relief lasting at
least 4 months
PRF of medial branch is a successful
intervention in selected patients with
no complications
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in the larger clinical study to give a statistically signifi-
cant difference. With positive outcomes (treatment suc-
cess), we could also determine the length of follow-up
necessary in a full-scale clinical study in order to study
the duration of effects.Primary research question
Is it feasible to do a larger scale clinical study to study the
effectiveness of ‘PRF treatment of DRG as compared to
placebo’ in CLR? Feasibility (outcome) parameters studied:
(1) recruitment rate; (2) percentage of patients who go on
to complete the full study after enrolling as participants.Secondary research questions
1. Is pulsed radiofrequency of DRG effective for pain
relief - measured as a decrease in VAS, measured at
4 weeks?
2. Is application of PRF associated with any short-term
(at 4 weeks) or long-term persisting (beyond
3 months) side effects?
3. Is there any improvement in Oswestry Disability
Index (ODI) in patients of CLR after PRF; measured
at 4 weeks, 2 months, and 3 months?
4. Is there any decrease in analgesic (medications) use in
patients with CLR after application of PRF; measured
at 1 week, 4 weeks, 2 months, and 3 months?
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Methodology and techniques
Patients would be screened at St Joseph Hospital,
Hamilton, Canada, at their-East End Pain Clinic for CLR
of at least 4 months’ duration. Based on the history and
clinical examination, a diagnosis of CLR involving one or
more spinal segments is made and noted. The patient is
considered eligible for the study if a CT or MRI of lumbar
spine done within the last 4 months demonstrates path-
ology that is concordant with the patient’s clinical symp-
toms. The spinal level(s) targeted for treatment will be
based on clinical findings, for example if a patient exhibits
signs and symptoms of right L4 radiculopathy, and the
MRI demonstrates right paracentral disc herniations at
both L4-5 and L5-S1, only the L4 DRG will be targeted.
Patients fulfilling the inclusion criteria will be fully
explained about the nature of study, interventions involved
and the possible complications after which an informed
consent will be taken. Enrolled patients would be rando-
mized according to the method described and included in
the study according to previously randomized order. He/
she will also meet the assessor (blind to intervention), who
would note down the baseline parameters of the patient
and also collect a baseline ODI score along with noting
down other parameters. A patient having bilateral radicu-
lopathy will be treated for his most affected side in the
trial. A patient having CLR of more than one segment on
one side shall be treated for all the involved segments with
the same technique and counted as a single procedure or
intervention for the study. After checking for the informed
consent and other safety checklist, patient will only be
revealed as belonging to the study (not mentioning
whether it is a placebo/actual treatment). All operating
room (OR) personnel, including the physician performing
the intervention and the patient, shall be blind to the
randomization and treatment. The grouping code, hence
the actual treatment will only be known by the person op-
erating the RF machine. Only the RF technician shall be in
view of the working details of the RF machine and the
noise of the machine is cut by playing out a music or song.
This ensures blinding of all involved, except the RF techni-
cian. All interventions will be done as day-care procedures
in the OR. Patients would continue to use their medica-
tions as before. If the pain relief obtained necessitates de-
crease in the usage of medications that shall be recorded.
Similarly unsatisfactory pain relief obtained necessitating
increase in the dose or change of medications shall be
recorded. The other parameters to be used for statistical
analysis are collected as mentioned under data analysis.
The patient will have an established IV access. He would
be put in prone position. The involved area of back would
be made sterile using chlorohexidine 2% and draped. The
patient would be connected to continuous monitoring of 3
lead ECG, NIBP, and pulse oximetry. Sedation, if used willbe minimal (Grade I or II) to obtain the necessary re-
sponse of the patient. Under fluoroscopy guidance particu-
lar spinal segment(s) affected is (are) identified and
confirmed. LA using 2% lidocaine is infiltrated to the skin
at entry site. For both groups a RF needle (Bayliss: 22-G
needle, 5-mm curved active tip and 10 cm) is used. With
an appropriate fluoroscopy view the needle is inserted to
the target location in both the groups.
Target location: the DRG, which is an enlargement
formed by the dorsal nerve root just proximal to its junc-
tion with the spinal nerve, lies within the dural sleeve and
occupies the upper, medial part of the intervertebral for-
amen [46]. It is confirmed with an anteroposterior fluoros-
copy view in which it is advanced, if required, until the tip
is located one-third to halfway into the pedicle column.
Target confirmation [46]: appropriate fluoroscopic place-
ment of needle near DRG at the lumbar area is noted; on
anteroposterior X-ray projection, the DRG is described to
lie immediately behind the lateral aspect of the facet col-
umn at all spinal levels and on lateral X-ray projection, it is
localized to the dorsocranial quadrant of the intervertebral
foramen (IVF). Proximity of the needle to the DRG is
determined by appropriate sensory stimulation with 50 Hz,
at more than 0.4 V (avoids intra-ganglionic placement),
and less than or equal to 0.6 V; motor stimulation at 2 Hz
with threshold 1.5-2 times greater than sensory threshold
to avoid placement near the anterior nerve root. A radicu-
logram done also confirms the appropriate placement and
helps recognize intradural placement of the needle. Both
the groups will have their respective DRG stimulated for
sensory confirmation. Only lidocaine 1% 0.5 mL shall be
given in both groups before carrying out the treatment.
Treatment: once positioned the physician shall indicate
to the RF technician as ‘treatment’ only, at which time
either PRF or placebo (only continuing sensory stimulation
at a low frequency of 0.2 V is applied) without revealing.
Application of intervention: in Group A, PRF; PRF would
be applied for 120 s at 42°C. Group B, placebo; the needle
would be continuously stimulated at a low voltage to give
a sensation of PRF application and also to obtain the
necessary noise to blind the patients. In both groups the
same procedure is done at all the involved spinal
segmental levels. After the procedure the patient is shifted
to recovery area to be monitored, observed and managed
for any side effects. The observer, blind to the interven-
tions, will record the pain scores and also check for side
effects observed before the patient is discharged home.
Blinding and bias control: in our study, the patient, the
treating physician, and the assessor for the actual interven-
tion are all blinded. The randomization code, hence the ac-
tual treatment, will only be known and administered by
the person operating the RF machine. The randomization
will be concealed in sealed envelopes. Blinding of patients
will be achieved by randomization, use of similar technique
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continuing non-PRF stimulation in placebo group, use of
audio to mask the treatment sound. Blinding of the treating
physician and assessor will be achieved by not knowing the
randomization order and hence not aware of the actual
treatment.
Planned inclusion and exclusion criteria
Suitable patients older than 18 years, suffering from CLR
of at least 4 months or more and with concordant find-
ings on either MRI or CT are included. Included patients
must also have a VAS score of at least 6/10 (at presenta-
tion) and must be ready to provide informed patient
consent for participating in the study as a blind subject.
Exclusion criteria would include any patient having an
absolute contraindication to neuraxial injection in the
form coagulation disturbance anticoagulant therapy,
bleeding disorder, or infection at the site of injection;
patients with anatomical deformity or derangement,
either congenital or acquired such as extreme scoliosis,
previous implant or instrumentation, making it difficult
to access the foramen as evidenced by MRI, CT, or
plain X-rays; patients with cancer to account for their
symptoms; patients with known significant psychiatric
history; patients unable to communicate effectively in
English; patients with allergy to local anesthetics or
radiographic dye; patients with a history of acute
neurological weakness or neurodeficit in the affected
limb in terms of measurable motor weakness or abnormal
reflexes.
Duration of treatment and follow-up
Duration of treatment period will involve approximately
30 to 60 min of actual intervention done in the OR.
The duration of complete follow-up will be for 3 months
after the intervention with the following interval follow-
up assessments: (1) 30 min post-procedure in recovery,
(2) 24 h after - by a phone call (only VAS and side
effects); (3) at 1 week post-procedure visit to the
assessor (VAS, ODI, medications, side effects); (4) at 4 weeks
post-procedure visit to the observer for assessment for suc-
cess (VAS, ODI, medications, side effects); (5) at 2 months
post-procedure-visit to observer (VAS, ODI, medications,
side effects); (6) at 3 months post-procedure visit to the
observer - last follow-up visit (VAS, ODI, medications, side
effects).
Primary and secondary outcome measures
Primary
1. Recruitment rate: percentage of suitable patients
fulfilling the inclusion–exclusion criteria, recruited for
the actual study after informed consent. The final
assessment will be after the complete recruitment, atwhich time all the expected number of subjects (n=32)
must have been enrolled. Criteria for success would be
as expected recruitment of at least four patients per
month after fulfilling the selection criteria and with full
informed consent with at least 80% of eligible patients
fulfilling the selection criteria being recruited.
2. Percentage of patients continuing to be participants
for the whole study.
Participants retain the right to withdraw from the study
at any point. However all participants after intervention
shall be included in the final analysis, on intention to treat
principle. Any participant requesting for a withdrawal shall
be given the option of continuing medical care or epidural
or transforaminal ESI at the next available opportunity
(present standard of care).
Secondary
1. Effectiveness of PRF treatment of DRG, when
compared to placebo, as a treatment in patients with
CLR: outcome measured as decrease in VAS scores (0
to 10) from baseline measured at recruitment. For
definition of success we would consider at least 50%
decrease in VAS scores assessed at 4 weeks.
2. Assessment of short-term side effects: percentage of
patients having side effects after PRF treatment assessed
at 1 week, compared with the placebo group.
Assessment of persisting side effects: percentage of
patients having side effects after PRF treatment, beyond
1 week, compared with placebo group. Short-term side
effects (within 1 week – recorded at the first visit):Nausea
Headache
Transient increase in pain
Fever (temperature in°C)
Transient paresis/paraesthesia
DysesthesiaLong-term side effects (persisting side effects
assessed at visits 1 week and at 6 weeks):







3. Improvement in ODI: success defined as at least
50% improvement (or decrease) in ODI measured
at 4 weeks, compared with placebo group.
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Rationale behind the assessment of interventions for
success at 4 weeks
1. Four weeks can be considered as the optimum time
at which the therapeutic effect of PRF would be at
its maximum.
2. There is a theoretical possibility of local anesthetic
action in either group, which can be eliminated at
4 weeks.
3. Even if there has been a placebo effect it is important
to know whether it is sustained at 4 weeks, in
comparison to the actual treatment effect.
4. To allow appropriate time for a decrease in ODI
(functional assessment) to happen as a result of
decreasing pain.
Trial design, outline, and flow chart
Sample size, recruitment rate
Sample size has been determined based on feasibility con-
siderations. Total duration of recruitment planned is 8
(clinically active) months. The proposed target is recruit-
ment for 8 months, with an expectation of at least four
patients every month, with a total of 32 patients for the
study. Potential to recruit patients, as four patients every
month has been calculated based on the transforaminal
steroid injections (TFESI) performed in the last 3 to
6 months and booked for the next 3 to 6 months (calcu-
lated as monthly) at St Joseph’s Healthcare; data obtained
from St Joseph’s Healthcare, Department of Anesthesia
and Pain. TFESI represents a well-accepted, presently per-
formed intervention for patients of CLR and most patients
suitable for that are potential recruits for this study.
Randomization
Patients will be randomly allocated to each group using
a 1:1 ratio. The allocation will be done in blocks using
block sizes of 2, 4, and 6.
Statistical tests
The characteristics of the trial participants will be described
using mean (standard deviation) or counts as appropriate.
We will use a flow diagram to summarize the flow of
patients in the trial. Feasibility outcomes will be reported as
counts (proportions).
Discussion
The results of this pilot study would primarily give us infor-
mation about the patient recruitment and study method-
ology. This is being done as there are no previous studies(RCTs) to indicate the successful effects of PRF in CLR.
The initial study proposal was to conduct an RCT compar-
ing PRF-DRG with TFESI, which have proven to be more
successful than midline ESIs for lumbar radiculopathy [52],
and are probably the most effective intervention available.
However our literature search showed that so far, there
were no RCTs involving sufficient participant numbers to
evaluate the efficacy of PRF. The only RCT by Van Zundert
et al. [16] on cervical radicular pain had only 19 partici-
pants in either group. Keeping this in mind we devised this
proof of concept study to evaluate the efficacy of PRF as
compared to placebo.
It is very challenging to devise and conduct a placebo
controlled trial in interventional pain medicine. Because of
the nature of the problem, which involves significant suffer-
ing for a long time, patients may be unwilling to participate
as blind participants. CLR patients would have had a trial of
most medications and simple interventions before they go
on to have complex spinal interventions, such as PRF-DRG.
It may also be difficult to have such patients to be under
long periods of follow-up after a blind intervention, espe-
cially if it is not of benefit to the patient. This trial would be
able to tell us whether we were able to recruit patients as
expected for the trial and also whether they continue to be
participants of the study for the whole duration. The other
important and novel aspect of this study which merits at-
tention is the technique of patient blinding during the pro-
cedure. Although we will not be formally evaluating the
blinding process, it will be interesting to know if we faced
significant challenges and if such a methodology needs to
be appropriately modified for a future trial. The study would
also assess the outcomes of pain relief from PRF compared
to placebo. Apart from telling us if PRF is successful, the
study would also indicate the difference in pain relief in
terms of absolute reduction in VAS scores. This is necessary
to assess the number of study participants for a future trial.
The assessment of side effects is included to understand if
there are major or minor side effects and risks which need
to be better studied and informed to the patients.Trial status
We are presently recruiting study participants. The trial
is registered on clinicaltrials.gov with the unique identi-
fier NCT01117870. We only require two more partici-
pants to complete the recruitment process. We have also
completed interventions on 28/32 patients.Abbreviations
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